Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
Authors
J. Guigay, J. Fayette, A.F. Dillies, C. Sire, J.N. Kerger, I. Tennevet, J.P. Machiels, S. Zanetta, Y. Pointreau, L. Bozec Le Moal, S. Henry, A. Schilf, J. Bourhis